Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 13Neoplasm Metastasis 2Endometrial Neoplasms 2Colorectal Neoplasms 2Solid Tumors 1PIK3CA-Mutated Cancers 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Metastatic Castration-Resistant Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fulvestrant 4ribociclib 2palbociclib 2Irinotecan 2Gemcitabine 2venetoclax 1tivozanib 1serabelisib 1sapanisertib 1niraparib 1lorlatinib 1liposomal doxorubicin 1inavolisib 1exemestane 1encorafenib 1cemiplimab 1binimetinib 1abemaciclib 1Taxes 1Tamoxifen 1STX-478 1Paclitaxel 1Metformin 1Lomustine 1Letrozole 1Imlunestrant 1Doxorubicin 1Cetuximab 1Carboplatin 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × inavolisib × 90 days × Clear all
NCT07522697 2026-04-13

MITO END-4

National Cancer Institute, Naples

Phase 2 Not yet recruiting
48 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡